CYTOMED THERAPEUTICS LIMITED

Contributing Author

Recent Articles by CYTOMED THERAPEUTICS LIMITED

Dec-08	CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia GDTC GlobeNewswire
Nov-18	CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India GDTC GlobeNewswire
Nov-06	CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy GDTC GlobeNewswire
Oct-22	CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% GDTC GlobeNewswire
Oct-14	CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets GDTC GlobeNewswire
Oct-02	CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia GDTC GlobeNewswire
Aug-28	Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition GDTC GlobeNewswire
Aug-18	CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program GDTC GlobeNewswire
Jul-21	Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies GDTC GlobeNewswire